Forward Looking Statement & Non-GAAP Disclaimer

This presentation may contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax’s plans, objectives, outlook, expectations and intentions, including the intended separation of Colfax’s fabrication technology and specialty medical technology businesses (the “Separation”), and the timing, method and anticipated benefits of the Separation, the expected benefits and contributions of the Mathys acquisition and the timing of such closing, and other statements that are not historical or current fact. Forward-looking statements are based on Colfax’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax’s results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic, including the rise, prevalence and severity of variants of the virus, actions by governments, businesses and individuals in response to the outbreak, such as the scope and duration of the outbreak, the nature and effectiveness of government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions, the impact on creditworthiness and financial viability of customers; risks relating to the Separation, including the final approval of the Separation by Colfax’s board of directors, the uncertainty of regulatory approvals, and a favorable tax opinion and/or ruling from the Internal Revenue Service, Colfax’s ability to satisfactorily complete steps necessary for the Separation and related transactions to be generally tax-free for U.S. federal income tax purposes, the ability to satisfy the necessary conditions to complete the Separation on a timely basis, or at all, the ability to realize the anticipated benefits of the Separation, developments related to the impact of the COVID-19 pandemic on the Separation, and the financial and operating performance of each company following the Separation; other impacts on Colfax’s business and ability to execute business continuity plans; and the other factors detailed in Colfax’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Colfax’s filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This presentation speaks only as of the date hereof. Colfax disclaims any duty to update the information herein.

The term “Colfax” in reference to the activities described in this presentation may mean one or more of Colfax’s global operating subsidiaries and/or their internal business divisions and does not necessarily indicate activities engaged in by Colfax Corporation.

Colfax has provided in this presentation financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”). These non-GAAP financial measures may include one or more of the following: adjusted net income from continuing operations, adjusted net income margin from continuing operations, adjusted net income per diluted share from continuing operations, adjusted EBITA (earnings before interest, taxes and amortization), adjusted EBITDA (adjusted EBITA plus depreciation and other amortization), adjusted EBITA margin, adjusted EBITDA margin, organic sales growth, and free cash flow. Colfax also provides adjusted EBITA, adjusted EBITDA, adjusted EBITA margin and adjusted EBITDA margin on a segment basis.

- Adjusted net income from continuing operations represents net income (loss) from continuing operations excluding restructuring and other related charges, European Union Medical Device Regulation (“MDR”) and other costs, pension settlement gain, debt extinguishment charges, acquisition-related amortization and other non-cash charges, and strategic transaction costs. Colfax also presents adjusted net income margin from continuing operations, which is subject to the same adjustments as adjusted net income from continuing operations.
- Adjusted net income per diluted share from continuing operations represents adjusted net income from continuing operations divided by the number of adjusted diluted weighted average shares. Both GAAP and non-GAAP diluted net income per share data are computed based on weighted average shares outstanding and, if there is net income from continuing operations (other than net loss), during the period (adjusted diluted weighted average shares outstanding in the same year). Colfax also presents adjusted net income margin from continuing operations, which is subject to the same adjustments as adjusted net income from continuing operations.
- Adjusted EBITA represents net income (loss) from continuing operations excluding restructuring and other related charges, MDR and other costs, acquisition-related amortization and other non-cash charges, and strategic transaction costs, as well as income tax expense (benefit) and interest expense, net. Colfax presents adjusted EBITA margin, which is subject to the same adjustments as adjusted EBITA. Further, Colfax presents adjusted EBITA (and adjusted EBITA margin) on a segment basis, which excludes the impact of strategic transaction costs and acquisition-related amortization and other non-cash charges from segment operating income.
- Organic sales growth (decline) excludes the impact of acquisitions and foreign exchange rate fluctuations. Organic sales-per-day growth (decline) represents Organic sales growth (decline) adjusted for additional or fewer selling days calculated based on the global average selling days particular to each segment.
- Free cash flow represents cash flow from operating activities less purchases of property, plant and equipment.

These non-GAAP financial measures assist Colfax management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are a function of and/or size that occur with inconsistent frequency or relate to discrete restructuring that are fundamentally different from the ongoing productivity improvements of the Company. Colfax’s management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures provided in the appendix to this presentation.

In this presentation under increasing 2021 EPS & Cash Flow Outlook, Colfax presents forward-looking adjusted EPS and free cash flow guidance. Colfax does not provide such outlook on a GAAP basis because changes in the items that Colfax excludes from GAAP to calculate adjusted EPS can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of Colfax’s routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on an outlook done on a GAAP basis. These excluded items could have a significant impact on the Company’s GAAP financial results.
Q2 2021 Highlights

- Adjusted EPS of $0.56 exceeded guidance ($0.48-$0.53)
- Organic sales-per-day growth of +48% vs 2020; +5% vs 2019
  - Share gains continue in industrial and med tech platforms
- Record margins of 16.4% at ESAB despite pressures from inflation
- Increasing guidance for full year adjusted EPS
- Expanding MedTech Reconstructive business with the acquisition of Mathys
- Great progress on separation, targeted for Q1 2022 completion

Strong Operating and Strategic Execution

Refer to Appendix for non-GAAP reconciliation and footnotes.
Making significant progress to create two independent publicly traded companies, ESAB and MedTechCo, in a tax-free separation

Standing-up ESAB public company support capabilities, expect it to operate with initial net leverage of 2.5x-3.0x upon separation

Selected new MedTechCo name, will unveil it later this year

Significant progress creating the two separate Boards of Directors with a combination of continuity and new members

Continue to target completion in Q1 2022
Record Margins at ESAB

<table>
<thead>
<tr>
<th>Year</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>1H 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>aEBITA Margin Expansion</td>
<td>11.5%</td>
<td>16.3%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sustainable Margin Improvement

- CBS driving operational excellence
  - Productivity and sourcing improvements
  - SG&A transformation
  - Rooftop reduction
  - Dynamic & value pricing
  - Inventory optimization
- Strategic objectives
  - Accelerate new product introductions
  - Expand exposure to higher growth segments
  - Execute attractive accretive acquisitions

Continuously Improving our Capabilities to Consistently Drive Margins Higher
Building Out Our MedTech Platform for Faster Growth

**Acquisition Criteria**
- Fuels growth
- Expands market reach
- Accelerates strategy
- Accretive to gross margins
- Creates Scale

**Significant Funnel of Additional Acquisition Opportunities**

**Strengthen & Extend Current Business**
- Recon Geographical Expansion
- Foot & Ankle Expansion
- High Growth High Margin P&R
- Digital Solutions & Technologies

**Ortho Market Expansion**
- High Growth Sub-segments
- Orthopedic Enabling Devices

**Logical MedTech Adjacencies**
- Technology Application in Other Markets
- Minimally Invasive Surgery
- Clinic-based Adjacencies

**Geographical and product portfolio expansions add significant growth opportunities**

Establishes dedicated business in fast-growing, high-gross margin foot and ankle market

Expands product portfolio into faster-growing high-power laser segment

Strategic investment in Computer Assisted Surgery (CAS) technologies

**Establishes dedicated business in fast-growing, high-gross margin foot and ankle market**

**Expands product portfolio into faster-growing high-power laser segment**

**Strategic investment in Computer Assisted Surgery (CAS) technologies**
Acquisition of Mathys, A European Leader in Orthopedic Implants

Overview

- Acquired Mathys AG Bettlach, a Swiss-based International orthopedics leader (acquisition closed on [July 28\textsuperscript{th}])
- Globalizes fast-growing Reconstructive segment
- Mathys has long history of innovation and clinically proven surgical solutions

Financial Profile & Terms

- Expecting sales of approximately $150 million in 2022, all sales outside the U.S.
- Projecting EBITDA of $15 to $20 million in 2022
- Acquisition consideration of approximately $285 million, financed with 6.5 million shares of Colfax common stock
Mathys Business Overview

- European orthopedics leader focused on developing innovative products for reconstructive joint replacement
- Full line provider; historical MSD growth driven by above-market growth in hip and shoulder

**Leading Products & Solutions**

**Extensive Direct EU Sales Channel & Strong Local Brand Recognition**

**Develops & Manufactures Orthopedic Ceramic Technologies**

- Mathys is one of the few manufacturers of ceramic components for orthopedic implants, with extensive clinical history
- Opportunity to leverage competence for future innovation
Strategic Benefits from Mathys Acquisition

- **Accelerates growth opportunities**
  - Acquisition creates a global platform and significantly expands addressable market
  - Highly complementary product lines and footprint
  - Accelerates growth opportunities in knee with EMPOWR™; shoulder with AltiVate®
  - Sustain well above market hip growth with dual mobility and strong Mathys pipeline

- **Strong margin improvement path**
  - Increased scale and operational synergies – will drive Mathys to be accretive to DJO margins and also contribute to US margins over time
  - Mix improvement from accelerating extremities growth and growth in attractive knee segments
  - Add additional direct markets over time

---

**A Winning Combination!**

---

**Pro Forma Reconstructive Business Sales (~$0.5B)**

- **DJO**
- **MATHYS European Orthopaedics**
- **Combined**

---

**U.S.**

- **DJO**
- **U.S.**
- **Combined**

---

**ROW**
Creating a $1B+ Reconstructive Platform

- Built on a foundation of delivering superior patient outcomes
  - 17% organic growth CAGR in Recon from 2014-2019
  - Consistent share gain across all categories
- Overweighted to extremities to capitalize on higher market growth areas
  - Fast-growing shoulder franchise
  - Newly created foot & ankle growth engine
- Mathys acquisition + growth acceleration from geography & product synergies
- Active funnel of strategic opportunities

2021e PF
~$0.5B sales

2026e
$1.0B+ sales

Double-digit organic CAGR

Proven Playbook to Drive Innovation and Above-Market Growth
Q2 2021 Financial Highlights

<table>
<thead>
<tr>
<th></th>
<th>Q2 2020</th>
<th>Q2 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Sales</td>
<td>$620</td>
<td>$986</td>
</tr>
<tr>
<td>Gross Profit Margin</td>
<td>$241</td>
<td>$419</td>
</tr>
<tr>
<td></td>
<td>38.9%</td>
<td>42.5%</td>
</tr>
<tr>
<td>Adj. EBITA Margin</td>
<td>$45</td>
<td>$130</td>
</tr>
<tr>
<td></td>
<td>7.3%</td>
<td>13.2%</td>
</tr>
<tr>
<td>Adj. EBITDA Margin</td>
<td>$70</td>
<td>$156</td>
</tr>
<tr>
<td></td>
<td>11.2%</td>
<td>15.9%</td>
</tr>
<tr>
<td>Adj. EPS</td>
<td>$0.09</td>
<td>$0.56</td>
</tr>
<tr>
<td>Free Cash Flow</td>
<td>$18</td>
<td>$58</td>
</tr>
</tbody>
</table>

- MedTech volumes grew over 2019 levels, expect same for ESAB in 2H
- Successfully protected profit from significant raw material inflation; gross margin performance includes ~200 bps compression
- Benefits of revenue recovery, restructuring actions reading through to aEBITA margin improvements
- Q2 adj. tax rate of 21.3%; expect 22-23% rate for full year
- Better-than-expected operating performance contributed to strong aEPS beat
- Cash flow processes operating effectively, results ramping as expected

Free cash flow represents operating cash flow less purchases of property, plant and equipment
Free cash flow (FCF) conversion represents FCF divided by adjusted net income
Refer to Appendix for non-GAAP reconciliation and footnotes
Q2 2021 Medical Technology Highlights

- Q2 organic sales-per-day increased 54%
  - +3% organic SPD vs. Q2 2019
  - Reported sales include 11% benefit from acquisitions
  - Recon organic sales-per-day increased 59%; +10% vs 2019
  - P&R organic sales-per-day increased 50%; +1% vs 2019
- aEBITA margins of 13.5% increased 330 bps sequentially vs Q1, aEBITA margins excluding acquisitions of 14.2%
  - Margins reflect higher costs due to supply chain constraints
- Expect continued demand improvement in 2H with accelerating growth over 2019 levels

<table>
<thead>
<tr>
<th></th>
<th>Q2 2021</th>
<th>Q2 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjusted EBITDA</td>
<td>$48.2</td>
<td>$6.5</td>
</tr>
<tr>
<td></td>
<td>13.5%</td>
<td>3.2%</td>
</tr>
</tbody>
</table>

**Q2 2021 Adjusted EBITDA**
- Q2 21 = $64.4/18.1%
- Q2 20 = $21.4/10.4%

**Q2 Adjusted EBITA Margins**
- $206.0
- $356.1
- $6.5
- $48.2

Refer to Appendix for non-GAAP reconciliation and footnotes.
Q2 2021 ESAB Highlights

- Q2 organic sales-per-day increased 44%:
  - +6% vs. 2019, volumes returning back to 2019 levels
  - Strong sales growth from developing regions & medical applications
  - Reported sales increased 52%, includes +5% impact from FX and +3% impact from additional selling days
  - Price impacted Q2 sales by +11%

- aEBITA margins improved 380 bps YoY to a record high of 16.4%

- Restructuring programs expected to drive $25-$30mm of savings during 2021

Strong YTD Growth and Margin Expansion; Strengthened Full Year Outlook

Refer to Appendix for non-GAAP reconciliation and footnotes.
Increasing 2021 EPS & Cash Flow Outlook

**Guidance Update** (includes Mathys & related financing)

- Raising aEPS guidance to **$2.10 - $2.20** (previously **$2.05 - 2.15**)
- FY aEBITDA projected to be **$600 - $625mm**
- Raising FY FCF to >**$275mm** (previously >$250mm)
- Q3 Guidance: aEPS of **$0.50 - $0.55**

**Colfax**
- Reported sales +21-23%
  - Organic +19-21% (including ~11 pts of price)
- EBITDA margins 17%+

**ESAB**
- Reported sales +28-31%
  - Organic +14-16%
  - Acquisitions +12-13%
- EBITDA margins
  - Core 20%+
  - Acquisitions ~10%

**Significant Momentum of Growth, Profit, Cash Flow**

Refer to Appendix for non-GAAP reconciliation and footnotes.
Strong outperformance in Q2, expect 2H recovery trajectory to further strengthen

Increased full year aEPS outlook to $2.10-$2.20 and free cash flow to $275 million or more

Acquired Mathys, successfully globalizing our Recon platform and reshaping our MedTech business for additional growth

Great progress on separation, remains targeted for Q1 2022 completion
Appendix
### Q2 Sales Growth Detail

#### MedTech Q2 Sales

<table>
<thead>
<tr>
<th></th>
<th>Q2 2020</th>
<th>Q2 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>$206.0</td>
<td>$356.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>vs. Q2 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organic Sales-Per-Day Growth</td>
<td>54.1 %</td>
</tr>
<tr>
<td>Additional Selling Days</td>
<td>5.0 %</td>
</tr>
<tr>
<td>Acquisitions</td>
<td>11.1 %</td>
</tr>
<tr>
<td>FX Translation</td>
<td>2.7 %</td>
</tr>
<tr>
<td>Total Change</td>
<td>72.9 %</td>
</tr>
</tbody>
</table>

#### ESAB Q2 Sales

<table>
<thead>
<tr>
<th></th>
<th>Q2 2020</th>
<th>Q2 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>$414.4</td>
<td>$629.8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>vs. Q2 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales-per-day (Volume)</td>
<td>33.7 %</td>
</tr>
<tr>
<td>Additional Selling days (volume)</td>
<td>3.2 %</td>
</tr>
<tr>
<td>Price</td>
<td>10.6 %</td>
</tr>
<tr>
<td>FX Translation</td>
<td>4.5 %</td>
</tr>
<tr>
<td>Total Change</td>
<td>52.0 %</td>
</tr>
</tbody>
</table>

*Note: Dollars in millions. Some periods may not foot due to rounding.*
## Non-GAAP Reconciliation

<table>
<thead>
<tr>
<th>Non-GAAP Reconciliation</th>
<th>July 2, 2021</th>
<th>July 3, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adjusted Net Income and Adjusted Net Income Per Share</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net income (loss) from continuing operations attributable to Colfax Corporation(1) (GAAP)</td>
<td>$30.3</td>
<td>$(3.6)</td>
</tr>
<tr>
<td>Restructuring and other related charges - pretax(2)</td>
<td>5.5</td>
<td>11.2</td>
</tr>
<tr>
<td>MDR and other costs - pretax(3)</td>
<td>1.9</td>
<td>1.0</td>
</tr>
<tr>
<td>Debt extinguishment charges - pretax</td>
<td>29.9</td>
<td>-</td>
</tr>
<tr>
<td>Acquisition-related amortization and other non-cash charges - pretax(4)</td>
<td>39.0</td>
<td>36.1</td>
</tr>
<tr>
<td>Strategic transaction costs - pretax(5)</td>
<td>8.0</td>
<td>1.7</td>
</tr>
<tr>
<td>Pension settlement gain - pretax</td>
<td>(11.2)</td>
<td>-</td>
</tr>
<tr>
<td>Tax adjustment(6)</td>
<td>(15.8)</td>
<td>(33.7)</td>
</tr>
<tr>
<td><strong>Adjusted net income from continuing operations (non-GAAP)</strong></td>
<td><strong>$87.5</strong></td>
<td><strong>$12.7</strong></td>
</tr>
</tbody>
</table>

| Adjusted net income per share - diluted from continuing operations (non-GAAP) | $0.36 | $0.09 |
| Net income (loss) per share - diluted from continuing operations (GAAP) | $0.19 | $(0.03) |

---

\(1\) Net income (loss) from continuing operations attributable to Colfax Corporation for the respective periods is calculated using Net income (loss) from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes, of $1.1 and $0.4 for the three months ended July 2, 2021 and July 3, 2020, respectively.

\(2\) Restructuring and other related charges includes $0.9 of expense classified as Cost of sales on our Condensed Consolidated Statements of Operations for the three months ended July 3, 2020.

\(3\) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations for all periods presented.

\(4\) Includes amortization of acquired intangibles and fair value charges on acquired inventory.

\(5\) For the three months ended July 2, 2021, Strategic transaction costs includes costs related to the proposed separation of our fabrication technology and medical technology businesses. For the three months ended July 3, 2020, Strategic transaction costs includes costs incurred for the acquisition of DJO.

\(6\) The effective tax rates used to calculate adjusted net income and adjusted net income per share were 21.3% and 21.5% for the three months ended July 2, 2021 and July 3, 2020, respectively.

---

*Note: Dollars in millions. Some periods may not foot due to rounding.*
Non-GAAP Reconciliation

<table>
<thead>
<tr>
<th></th>
<th>Fabrication Technology</th>
<th>Medical Technology</th>
<th>Total Colfax Corporation</th>
</tr>
</thead>
<tbody>
<tr>
<td>For the three months ended July 3, 2020</td>
<td>$414.4</td>
<td>$206.0</td>
<td>$620.4</td>
</tr>
</tbody>
</table>

**Components of change:**

1. **Existing businesses**
   - Fabrication Technology: $196.2, 47.3%
   - Medical Technology: $121.6, 59.0%
   - Total Colfax Corporation: $517.8, 51.2%

2. **Acquisitions**
   - Fabrication Technology: $0.7, 0.2%
   - Medical Technology: $22.9, 11.1%
   - Total Colfax Corporation: $23.6, 3.8%

3. **Foreign currency translation**
   - Fabrication Technology: $18.5, 4.5%
   - Medical Technology: $5.6, 2.7%
   - Total Colfax Corporation: $24.1, 3.9%

For the three months ended July 2, 2021:

- Fabrication Technology: $629.8
- Medical Technology: $556.1
- Total Colfax Corporation: $985.9

Note: Dollars in millions. Some periods may not foot due to rounding.

(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of change due to factors such as price, product mix and volume. Includes the favorable sales impact of approximately 3% in Fabrication Technology and 5% in Medical Technology due to additional selling days, calculated based on the global average selling days particular to each segment.

(2) Represents the incremental sales as a result of acquisitions closed subsequent to the beginning of the prior year respective period.

(3) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.
## Non-GAAP Reconciliation

### Three Months Ended July 2, 2021

<table>
<thead>
<tr>
<th></th>
<th>Fabrication Technology</th>
<th>Medical Technology</th>
<th>Corporate and Other</th>
<th>Total Colfax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td>$629.8</td>
<td>$358.1</td>
<td>$-</td>
<td>$985.9</td>
</tr>
<tr>
<td>Operating income (loss) (GAAP)</td>
<td>90.9 14.4%</td>
<td>143 4.0%</td>
<td>(19.3)</td>
<td>75.9 7.7%</td>
</tr>
<tr>
<td>Restructuring and other related charges</td>
<td>5.5</td>
<td>2.0</td>
<td>-</td>
<td>5.5</td>
</tr>
<tr>
<td>MDR and other costs(i)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Segment operating income (loss) (non-GAAP)</td>
<td>64.4 15.0%</td>
<td>18.2 5.1%</td>
<td>(19.3)</td>
<td>81.3 8.5%</td>
</tr>
<tr>
<td>Strategic transaction costs(ii)</td>
<td>0.1</td>
<td>-</td>
<td>-</td>
<td>0.0</td>
</tr>
<tr>
<td>Acquisition-related amortization and other non-cash charges(iii)</td>
<td>0.1 20.0%</td>
<td>-</td>
<td>-</td>
<td>10.0</td>
</tr>
<tr>
<td>Adjusted EBITA (non-GAAP)</td>
<td>$183.6 16.4%</td>
<td>$48.2 13.5%</td>
<td>$(11.1)</td>
<td>$130.3 13.2%</td>
</tr>
<tr>
<td>Depreciation and other amortization</td>
<td>9.6</td>
<td>16.2</td>
<td>0.3</td>
<td>26.2</td>
</tr>
<tr>
<td>Adjusted EBITDA (non-GAAP)</td>
<td>$113.2 18.0%</td>
<td>$64.4 18.1%</td>
<td>$(11.1)</td>
<td>$156.5 15.0%</td>
</tr>
</tbody>
</table>

### Three Months Ended July 3, 2020

<table>
<thead>
<tr>
<th></th>
<th>Fabrication Technology</th>
<th>Medical Technology</th>
<th>Corporate and Other</th>
<th>Total Colfax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td>$414.4</td>
<td>$200.0</td>
<td>$-</td>
<td>$620.4</td>
</tr>
<tr>
<td>Operating income (loss) (GAAP)</td>
<td>37.5 9.0%</td>
<td>(26.9) -13.0%</td>
<td>(15.6)</td>
<td>(4.9) -0.8%</td>
</tr>
<tr>
<td>Restructuring and other related charges(ii)</td>
<td>0.1</td>
<td>-</td>
<td>-</td>
<td>0.0</td>
</tr>
<tr>
<td>MDR and other costs(i)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Segment operating income (loss) (non-GAAP)</td>
<td>43.6 10.5%</td>
<td>(20.8) -10.3%</td>
<td>(15.6)</td>
<td>7.2 1.2%</td>
</tr>
<tr>
<td>Strategic transaction costs(ii)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acquisition-related amortization and other non-cash charges(iii)</td>
<td>8.2 27.3%</td>
<td>-</td>
<td>-</td>
<td>36.1</td>
</tr>
<tr>
<td>Adjusted EBITA (non-GAAP)</td>
<td>$52.4 12.6%</td>
<td>$6.5 3.2%</td>
<td>$(13.8)</td>
<td>$45.1 7.3%</td>
</tr>
<tr>
<td>Depreciation and other amortization</td>
<td>9.5</td>
<td>14.8</td>
<td>0.2</td>
<td>24.4</td>
</tr>
<tr>
<td>Adjusted EBITDA (non-GAAP)</td>
<td>$61.7 14.9%</td>
<td>$21.4 10.4%</td>
<td>$(13.6)</td>
<td>$69.5 11.2%</td>
</tr>
</tbody>
</table>

---

(i) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations for all periods presented.

(ii) For the three months ended July 2, 2021, Strategic transaction costs includes costs related to the proposed separation of our fabrication technology and medical technology businesses. For the three months ended July 3, 2020, Strategic transaction costs includes costs incurred for the acquisition of DJO.

(iii) Includes amortization of acquired intangibles and fair value charges on acquired inventory.

Note: Dollars in millions. Some periods may not foot due to rounding.
Non-GAAP Reconciliation

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Net cash provided by operating activities</td>
<td>$162.8</td>
<td>$84.4</td>
<td>$78.4</td>
</tr>
<tr>
<td>Purchases of property, plant and equipment</td>
<td>(44.6)</td>
<td>(24.5)</td>
<td>(20.1)</td>
</tr>
<tr>
<td>Free cash flow</td>
<td>$118.1</td>
<td>$59.8</td>
<td>$58.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Net cash provided by operating activities</td>
<td>$93.2</td>
<td>$56.2</td>
<td>$37.0</td>
</tr>
<tr>
<td>Purchases of property, plant and equipment</td>
<td>(50.4)</td>
<td>(31.1)</td>
<td>(19.3)</td>
</tr>
<tr>
<td>Free cash flow</td>
<td>$42.8</td>
<td>$25.1</td>
<td>$17.7</td>
</tr>
</tbody>
</table>

Note: Dollars in millions. Some periods may not foot due to rounding.
Non-GAAP Reconciliation

### Fabrication Technology

<table>
<thead>
<tr>
<th></th>
<th>Year Ended December 31, 2015</th>
<th>Six Months Ended July 2, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net sales</strong></td>
<td>$1,985.2</td>
<td>$1,197.9</td>
</tr>
<tr>
<td><strong>Operating income (GAAP)</strong></td>
<td>168.6</td>
<td>170.1</td>
</tr>
<tr>
<td><strong>Restructuring and other related charges</strong></td>
<td>29.7</td>
<td>6.6</td>
</tr>
<tr>
<td><strong>Intangible asset impairment charge</strong></td>
<td>1.5</td>
<td>-</td>
</tr>
<tr>
<td><strong>Segment operating income (non-GAAP)</strong></td>
<td>199.8</td>
<td>176.7</td>
</tr>
<tr>
<td><strong>Strategic transaction costs</strong></td>
<td>-</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Acquisition-related amortization and other non-cash charges</strong></td>
<td>29.4</td>
<td>18.2</td>
</tr>
<tr>
<td><strong>Adjusted EBITA (non-GAAP)</strong></td>
<td>$229.2</td>
<td>$195.0</td>
</tr>
</tbody>
</table>

(1) Strategic transaction costs includes costs related to the proposed separation of our fabrication technology and medical technology businesses.
(2) Includes amortization of acquired intangibles and fair value charges on acquired inventory.

*Note: Dollars in millions. Some periods may not foot due to rounding.*